This study was aimed at determining whether the chick cardiomyocyte micromass (MM) system could be employed to predict the teratogenicity/embryotoxicity of exogenous chemicals. Two documented teratogens/embryotoxins, sodium valproate (the sodium salt of valproic acid; VPA) and all-trans retinoic acid (tRA), were used in the initial phase of the study. White Leghorn 5-day-old embryo hearts were dissociated to produce a cardiomyocyte suspension in Dulbecco's Modified Eagle's Medium. Cultures were incubated at 37°C in 5% CO2 in air, and observations were made every 24 hours over 5 days, for the detection of beating. Culture viability was assessed by using the resazurin reduction assay for determining culture activity and the kenacid blue assay for determining cell number. It was found that tRA significantly reduced cell activity and beating, whilst not affecting total cell number. VPA up to 500μM induced no cytotoxicity in the MM cardiomyocyte cultures, whilst all the VPA concentrations tested reduced beating. The results demonstrate the potential of the chick cardiomyocyte MM culture assay to identify teratogens/embryotoxins that alter functionality, which may result in a teratogenic outcome, whilst not causing cytotoxicity (direct embryotoxicity). This could form part of a screen for developmental toxicity related to cardiac function, whilst limb cultures and brain cultures based on the same system could be relevant to teratogenic effects on those tissues.
Anon. (2003). Proposal for a Regulation of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency and amending Directive 1999/45/EC and Regulation (EC) [on Persistent Organic Pollutants]. COM(2003) 644 final. 1321 pp., in six volumes. Brussels, Belgium: European Commission.
2.
BallsM., & KarcherW. (1995). The validation of alternative test methods. ATLA23, 884–886.
3.
SpielmannH., GenschowE., ScholzG., BrownN.A., PiersmaA.H., BradyM., ClemannN., HuuskonenH., PaillardF., BremerS., & BeckerK. (2001). Preliminary results of the ECVAM validation study on three in vitro embryotoxicity tests. ATLA29, 301–304.
4.
GenschowE., SpielmannH., ScholzG., SeilerA., BrownN., PiersmaA., BradyM., ClemannN., HuuskonenH., PaillardF., BremerS., & BeckerK. (2002). The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. ATLA30, 151–176.
5.
PiersmaA.H. (2004). Validation of alternative methods for developmental toxicity testing. Toxicology Letters149, 147–153.
NauH., HauckR.S., & EhlersK. (1991). Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacology & Toxicology69, 310–321.
8.
IqualM.M., SohhanT., & MahmudS.Z. (2001). The effects of lithium, valproic acid and carbamazepine during pregnancy and lactation. Journal of Toxicology — Clinical Toxicology39, 381–392.
9.
KozmaC. (2001). Valproic acid embryopathy: report of two siblings with further expansions of the phenotypic abnormalities and a review of the literature. American Journal of Medical Genetics98, 168–175.
10.
CotariuD., & ZaidmanJ.L. (1991). Developmental toxicity of valproic acid. Life Sciences48, 1341–1350.
11.
LindhoutD., MeinardiH., MeijerJ.W., & NauH. (1992). Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology42, 94–110.
12.
ThistedE., & EbbesenF. (1993). Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero.Archives of Diseases in Childhood69, 288–291.
13.
AndrewsJ.E., Ebron-McCoyM.T., BojicU., NauH., & KavlockR.J. (1997). Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentyonic acid (4-yn-VPA): cross-species evaluation in whole embryo culture. Teratology55, 314–318.
14.
SodhiP., PoddarB., & ParmarV. (2001). Fatal cardiac malformation in fetal valproate syndrome. Indian Journal of Pediatrics68, 989–990.
15.
WiegandU.W., HartmannS., & HummlerH. (1998). Safety of vitamin A: recent results. International Journal for Vitamin and Nutrition Research68, 411–416.
16.
LammerE.J., ChenD.T., HoarR.M., AgnishN.D., BenkeP.J., BraunJ.T., FernhoffP.M., GrixA.W.Jr., LottI.T., RichardJ.M., & SunS.C. (1985). Retinoic acid embryopathy. New England Journal of Medicine313, 837–841.
17.
GeelenJ.A.G. (1979). Hypervitaminosis A induced teratogenesis. CRC Critical Reviews in Toxicology6, 351–375.
18.
ColbertM.C. (2002). Retinoids and cardiovascular development defects. Cardiovascular Toxicology2, 25–29.
19.
BrownL.P., FosterJ.R., OrtonT.C., FlintO.P., & GibsonG.S. (1989). Inducibility and functionality of rat embryonic/foetal cytochrome P-450. Toxicology in Vitro3, 253–260.
20.
WigerR., StotumA., & BrunborgG. (1988). Estimating chemical developmental hazard in a chick embryo limb bud micromass system. Pharmacology and Toxicology62, 32–37.
21.
MeyerM.P., SwannK., BurnstockG., & ClarkeJ.D.W. (2001). The extracellular ATP receptor, cP2Y1, inhibits cartilage formation in micromass cultures of chick limb mesenchyme. Developmental Dynamics222, 494–505.
22.
L'HullierN., PrattenM.K., & ClothierR.H. (2002). The relative embryotoxicity of 1,3-dichloro-2-propanol on primary chick embryonic cells. Toxicology in Vitro16, 433–442.
23.
DukeP.J., Montufar-SolisD., HamazakiT., & SatoA. (1998). Clinorotation reduces number, but not size, of cartilaginous nodules formed in micromass cultures of mouse limb bud cells. Advances in Space Research21, 1065–1072.
24.
FlintO.P. (1987). An in vitro test for teratogens using cultures of rat embryo cells. In In Vitro Methods in Toxicology (ed. AtterwillC.K., & SteeleC.E.), pp. 339–363. Cambridge, UK: Cambridge University Press.
25.
FlintO.P., & OrtonT.C. (1984). An in vitro assay for teratogens with cultures of rat embryo midbrain and limb cells. Toxicology and Applied Pharmacology76, 383–395.
26.
AtterwillC.K., JohnstonH., & ThomasS.M. (1992). Models for the in vitro assessment of neurotoxicity in the nervous system in relation to xenobiotic and neurotrophic factor-mediated events. Neuro toxicology13, 39–54.
27.
BrownN., & WigerR. (1992). Comparison of rat and chick limb bud micromass cultures for developmental toxicity screening. Toxicology in Vitro6, 101–107.
28.
AtterwillC.K., HillierG., JohnstonH., & ThomasS.M. (1992). A tiered system for in vitro neurotoxicity testing. In The Brain in Bits and Pieces (ed. ZbindenG.), pp. 89–91. Zollikon, Switzerland: Verlag MTC.
29.
WigerR., TryggB., & HolmeJ.A. (1989). Toxic effects of cyclophosphamide in differentiating chicken limb bud cell culture using rat liver 9,000g supernatant or rat liver cells as an activation system: an ‘in vitro’ short-term test for proteratogens. Teratology40, 684–691.
30.
ClothierR.H., & SamsonR. (1996). Effects of surfactant retreatment in vitro: a method to evaluate changes in cell junctions and in cell viability. ATLA24, 859–865.
31.
ClothierR.H., StarzecG., PradelL., BaxterV., JonesM., CoxH., & NobleL. (2002). The prediction of human skin responses by using the combined in vitro fluorescein leakage/Alamar Blue (resazurin) assay. ATLA30, 493–504.
32.
GrayA.C., MaltonJ., & ClothierR.H. (2004). The development of a standardised protocol to measure squamous differentiation in stratified epithelia, by the fluorescein cadaverine incorporation technique. ATLA32, 91–100.
33.
KnoxP., UphillP.F., FryJ.R., BenfordD., & BallsM. (1986). The FRAME Multicentre project on in vitro cytotoxicity. Food and Chemical Toxicology24, 457–463.
34.
ClothierR.H., AtkinsonK.A., GarleM.J., WardR.K., & WillshawA. (1995). The development and evaluation of in vitro tests by the FRAME Alternatives Laboratory. ATLA23, 75–90.
35.
RenaultJ.Y., MelcionC., & CordierA. (1989). Limb bud cell culture for in vitro teratogen screening: validation of an improved assessment method using 51 compounds. Teratogenesis, Carcinogenesis, and Mutagenesis9, 83–96.
36.
GiroudA., & MartinetM. (1959). Teratogenesis by hypervitaminosis A in the rat, the mouse, the guinea pig and the rabbit. Archives Françaises de Pédiatrie16, 971–975.
37.
HamburgerV., & HamiltonH.L. (1951). A series of normal stages in the development of the chick embryo. Journal of Morphology88, 49–92.
38.
BrownN.A., SpielmannH., BechterR., FlintO.P., FreemanS.J., JelinekR.J., KochE., NauH., NewallD.R., PalmerA.K., RenaultJ., RepettoM.F., VogelR., & WigerR. (1995). Screening chemicals for reproductive toxicity: the current alternatives. ATLA23, 868–882.
39.
NaL., WartenbergM., NauH., HeschelerJ., & SauerH. (2003). Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth Defects Research67, 174–180.
40.
O'BrienJ., WilsonI., OrtonT., & PognanF. (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European Journal of Biochemistry267, 5421–5426.
41.
BigotK., de LangeJ., ArcherG., ClothierR.H., & BremerS. (1999). The relative semi quantification of the mRNA expression as a useful toxicological endpoint for the identification of embryotoxic/teratogenic substances. Toxicology in Vitro13, 619–623.
